Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Snipelisky

Advanced Heart Failure and Transplant Cardiology Weston, FL Medical Doctor

NPI 1699069088 CMS profile 212924

3100 Weston Rd, Weston, FL 33331

Open in the dashboard

General payments

$250,466

718 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$135,958 paid to institutions, not to them · program years 2023–2025

Through program year 2025, David Snipelisky of Weston, FL is reported in the CMS Open Payments database as having received $250,466 across 718 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $135,958 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,596 108
2024 General $32,261 98
2023 General $64,911 177
2022 General $54,648 158
2021 General $6,871 23
2020 General $14,283 45
2019 General $16,896 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Snipelisky
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to David Snipelisky were reported at $60,596. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year David Snipelisky Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $16,896 $863 $224–$4,562 $163
2020 $14,283 $452 $122–$3,992 $114
2021 $6,871 $550 $159–$3,571 $132
2022 $54,648 $729 $221–$4,357 $149
2023 $64,911 $1,002 $309–$5,827 $160
2024 $32,261 $931 $273–$5,204 $164
2025 $60,596 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $171,092 252 payments
  2. Impulse Dynamics (USA) Inc. $62,466 95 payments
  3. Abbott Laboratories $6,653 119 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $2,124 2 payments
  5. Novartis Pharmaceuticals Corporation $1,323 96 payments
  6. Abiomed $1,202 6 payments
  7. Alexion Pharmaceuticals, Inc. $1,095 12 payments
  8. Medtronic, Inc. $599 9 payments
  9. Boston Scientific Corporation $493 12 payments
  10. Biosense Webster, Inc. $459 12 payments
  11. Other $2,961 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $132,649 46 payments
  2. Honoraria $47,700 17 payments
  3. Travel and Lodging $37,325 160 payments
  4. Food and Beverage $20,643 489 payments
  5. Consulting Fee $12,100 3 payments
  6. Education $49 3 payments
Products named General payments · program years 2019–2025
  1. VYNDAQEL $163,540 235 payments
  2. OPTIMIZER Cardiovascular Device $43,334 66 payments
  3. OPTIMIZER Cardiovascular Device $43,334 66 payments
  4. Optimizer Cardiovascular $19,132 29 payments
  5. Optimizer Cardiovascular $18,718 26 payments
  6. VYNDAMAX $4,584 8 payments
  7. CARDIOMEMS $2,685 60 payments
  8. LifeVest $2,124 2 payments
  9. Impella $1,202 6 payments
  10. HeartMate 3 Left Ventricular Dev $1,190 15 payments
  11. Other $9,435 339 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,549

Median for Cardiology: 2,533

Drug cost

$3,851,674

Median for Cardiology: $485,213

Branded share of claims

44.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 118 $2,726,372
Vyndaqel Tafamidis Meglumine Brand 28 $583,418
Entresto Sacubitril/Valsartan Brand 246 $279,294
Farxiga Dapagliflozin Propanediol Brand 111 $108,493
Eliquis Apixaban Brand 81 $75,282
Jardiance Empagliflozin Brand 53 $51,242
Repatha Sureclick Evolocumab Brand 12 $10,621
Tacrolimus Generic 17 $3,605
Milrinone Lactate Generic 28 $2,901
Torsemide Generic 78 $2,038

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$133,730

Medicare's payments for the services billed

Medicare patients

254

Average age 72

Services billed

1,305

82 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Chronic kidney disease 70%
Ischemic heart disease 69%
Atrial fibrillation 62%
Diabetes 50%
Arthritis 44%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
$16,447 28 —
JARDIANCE
$213 53 —
XARELTO
$132 — —
Repatha
$50 12 —
CAMZYOS
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record